IDEAYA Reports Updated P-I Data of IDE849 (SHR-4849) for Relapsed SCLC and Neuroendocrine Carcinomas at ESMO 2026

Shots: IDEAYA’s partner Hengrui has presented updated P-I study data of IDE849 (SHR-4849; DLL3 TOP1 ADC) in 122 pts with relapsed SCLC & other NECs in China at ESMO 2026 In 2L SCLC, the therapy showed 72.5% ORR, mOS of 17.4mos & mPFS of 6.9mos, with 65.4% cORR in pts with brain metastases & 52.6% ORR in NECs; Grade ≥3 TRAEs were 33.3% at the 2.4mg/kg expansion dose Following Type C meetings with the US FDA, IDEAYA is targeting 2 global P-III registrational trials of IDE849 in ES-SCLC (post-Imdelltra) & NEC Ref: PR Newswire  |   Image: IDEAYA Biosciences  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post IDEAYA Reports Updated P-I Data of IDE849 (SHR-4849) for Relapsed SCLC and Neuroendocrine Carcinomas at ESMO 2026 appeared first on PharmaShots.